Thank you for your interest! Unfortunately this offer has ended.
For the latest deals and promotions, please sign up for our email newsletter below, or contact us now!
Sitemap
- About Us
- Gene Editing
- Animal & Cell Models
- Animal Models
- Humanized Immune-Checkpoint Mice
- Humanized Cytokine Mice
- Humanized GPCR Mice
- Other Humanized Models
- Immunodeficient Mice (B-NDG background)
- Immunodeficient Mouse Models (Non B-NDG background)
- Reporter Models
- Cre Mouse/Rat Models
- DTR Models
- Other Tool Models
- Disease Mouse Models
- Drug Target Knockout Mouse Models
- Other Knockout Mouse Models
- Cell Lines
- Animal Models
- Efficacy & Toxicity Studies
- Autoimmune & Inflammation Models
- Psoriasis Model
- Atopic Dermatitis Model
- Delayed type hypersensitivity model
- Acute Lung Injury & Inflammation Models
- Asthma Model
- Bleomycin-Induced Pulmonary Fibrosis Model
- Rheumatoid Arthritis Model
- Ovariectomy (OVX) induced Osteoporosis Model
- Osteoarthritis Model
- EAE Model
- LPS Mouse Model of Acute Inflammation
- Inflammatory Bowel Disease Model
- Systemic Lupus Erythematosus Model
- 5/6 Nephrectomy Chronic Kidney Disease Model
- Metabolic Disease Models
- NASH Mouse Models
- High-fat diet-induced obese (DIO) mouse model
- Type 2 Diabetes Mouse Model
- STZ Mouse Model
- Bile duct ligation-induced liver fibrosis Mouse Model
- TAA (Thioacetamide) -induced liver fibrosis Mouse Model
- Acetaminophen-induced Liver Injury Model
- Concanavalin A hepatitis model
- Atherosclerosis model
- In Vivo Pharmacology Services
- PK/PD Assays & In vitro Pharmacology Studies
- Efficacy & Toxicity Case Studies
- Autoimmune & Inflammation Models
- RenMice® Platforms
- Preclinical & Clinical Assets
- Antibody Hits Library
- Agonistic anti-CD40 IgG2 antibody YH003
- Anti-CTLA-4 IgG1 monoclonal antibody YH001
- Anti-OX40 IgG1 antibody YH002
- Agonistic anti-4-1BB IgG1 antibody YH004
- Anti-PD-1 x CD40 bispecific antibody YH008
- HER2 x TROP2 bispecific ADC YH012
- Antagonistic anti-CD40 fully human antibody YH015
- Careers
- News & Resources
- Investors
Product Categories
- Cre Mouse/Rat Models
- Drug Target Knockout Mouse Models
- DTR Models
- Humanized Cytokine Mice
- Humanized GPCR Mice
- Humanized Immune-Checkpoint Mice
- Humanized Tumor Cell Lines
- Immunodeficient Mice (B-NDG background)
- Immunodeficient Mouse Models (Non B-NDG background)
- Other Cancer Cell Lines
- Other Knockout Mouse Models
- Other Tool Models
- Reporter Models
Events
- Join BIOCYTOGEN at JPM Healthcare Conference 2025 | December 10, 2024
- Join BIOCYTOGEN at AET (Antibody Engineering & Therapeutics) US 2024 | November 15, 2024
- Join BIOCYTOGEN at BioFit 2024 | November 15, 2024
- Join BIOCYTOGEN at 2nd Cell Therapy For Autoimmune Disease Summit | November 15, 2024
- Join BIOCYTOGEN at Sino-American Pharmaceutical Professionals Association (SAPA), Connecticut 2024 | November 15, 2024
- Join BIOCYTOGEN at 7th SCBA Hepatology Division & CALS Annual Symposium | October 25, 2024
News
- Behind the Scene: Meet Brent, The Chicken-Raising, Mouse-Managing Expert at Biocytogen | November 14, 2024
- Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise | November 11, 2024
- Meet Hannah: A Journey Through Business Development with a Twist | September 10, 2024
- “RenBiologics” Collaboration Expands Rapidly, Providing Efficient Options for Novel Drug Development | August 12, 2024
- Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program | July 31, 2024
- SOTIO Enters into Multi-Target Antibody Agreement with Biocytogen to Expand ADC Pipeline | July 16, 2024
